Tango Therapeutics (NASDAQ:TNGX – Get Free Report) and Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.
Earnings and Valuation
This table compares Tango Therapeutics and Panbela Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tango Therapeutics | $42.51 million | 20.86 | -$101.74 million | ($1.13) | -7.35 |
| Panbela Therapeutics | N/A | N/A | -$25.26 million | ($280.98) | 0.00 |
Panbela Therapeutics has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Institutional & Insider Ownership
79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are held by institutional investors. 6.2% of Tango Therapeutics shares are held by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Tango Therapeutics and Panbela Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tango Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
| Panbela Therapeutics | 0 | 1 | 1 | 0 | 2.50 |
Tango Therapeutics currently has a consensus price target of $15.14, suggesting a potential upside of 82.44%. Panbela Therapeutics has a consensus price target of $500.00, suggesting a potential upside of 146,958.82%. Given Panbela Therapeutics’ higher probable upside, analysts clearly believe Panbela Therapeutics is more favorable than Tango Therapeutics.
Profitability
This table compares Tango Therapeutics and Panbela Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tango Therapeutics | -274.04% | -44.73% | -28.79% |
| Panbela Therapeutics | N/A | -70,194.55% | -269.84% |
Summary
Tango Therapeutics beats Panbela Therapeutics on 9 of the 14 factors compared between the two stocks.
About Tango Therapeutics
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
About Panbela Therapeutics
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
